



THE AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES

ANNUAL REPORT 2020

*ASID WOULD LIKE TO FORMALLY
RECOGNISE THE EFFORTS AND
EXPERTISE OF ITS INFECTIOUS
DISEASES, MICROBIOLOGY,
INFECTION CONTROL, AND
PUBLIC HEALTH COLLEAGUES,
INCLUDING THOSE WORKING
BEHIND THE SCENES
PROVIDING ADVICE AND
GUIDANCE TO THEIR FELLOW
HEALTHCARE PROFESSIONALS
DURING THIS CHALLENGING
TIME.*

**EXCERPT FROM A
STATEMENT
RELEASED BY ASID
ON 5 FEBRUARY 2020
AT THE BEGINNING
OF THE COVID-19
PANDEMIC.**



CONTENTS

2020 Year In Review	3
Board and Council	4
President's Report	5
Events and Webinars	7
Award Recipients	10
Advocacy and Communications	11
ASID Representation on Committees	12
Registered Charity	13
Honorary Treasurer's Report	14
Audited Financial Report 2020	14
Honorary Secretary's Report	15

2020 YEAR IN REVIEW

MEMBERSHIP

More than **1000** members
48% female



EVENTS AND WEBINARS

3 conferences
More than **20** webinars
(SIGs and COVID-19)
More than **1600** virtual and
260 F2F attendees

OZ BUG POSTS

Over **1850** posts by members
(the majority posted during the
height of COVID-19)



COMMITTEES

15 committees
118 committee members



POSITION STATEMENTS



9 position statements

TWITTER

90% increase in followers
since Dec 2019

ASID Board



President
Professor Allen Cheng



Immediate Past President
Professor Joshua Davis



Honorary Secretary
Professor Katie Flanagan



Honorary Treasurer
Dr Joseph Doyle



Board Director
Dr Brendan McMullen



Board Director
A/Prof Julia Clark



Board Director
A/Prof Patrick Charles

ASID Council (in addition to Board members).

- NZ Representative
- Advanced Trainee Reps
- ASA President
- ANZMIG Co Chair
- ANZMIG Co Chair
- ANZPID Chair
- HICSIG Chair
- JSAC Chair
- RCPA Representative
- Recent Fellow
- VACSIG Chair
- VHSIG Chair
- ZOOSIG Co-Chair
- ZOOSIG Co-Chair

- Dr Nigel Raymond
- Dr Aaron Bloch
- Prof Ben Howden
- Dr Orla Morrissey
- Dr Karina Kennedy
- Dr Asha Bowen
- Dr Andrew Stewardson
- Dr David Mitchell
- Dr Jenny Robson
- Dr Iain Abbott
- Prof Katie Flanagan
- Dr Joseph Doyle
- A/Prof David Looke
- Dr Rowland Cobbold

President's Report

Professor Allen Cheng



The year 2020 was a year of 'firsts' for ASID. We lived and worked through a pandemic; we welcomed our 1000th member; we held our first ever virtual Annual General Meeting; and we gained health promotion charity status.

The way our speciality responded to the events of 2020 should make us all proud.

From March onward it was a tense time for members, reflected especially on Ozbug which proved invaluable for sharing updates, opinions and information. ASID members stepped up, playing a key role in the response to COVID-19, serving on relevant committees at local, state and federal level; leading research efforts; communicating with the public via media; developing clinical guidelines; and working in hospitals assessing and treating patients.

As COVID-19 cases began to climb, ASID became a founding member of the National COVID-19 Clinical Evidence Taskforce and partnered with a diverse group of national peak bodies to provide clear and consistent guidance for the clinical care of Australian's with COVID-19. Well done to Julian Elliott, Joe Doyle, Asha Bowen and Brendan McMullan for their hard work.

We were able to participate in the public debate thanks to media activity during the year. Thank you to Josh who navigated ASID through the early pandemic phase until the AGM and then assisted me as ASID's spokesperson when I was occupied by my work in Victoria.

Like other organisations, our 2020 Events Calendar was thrown into disarray. We held the very successful inaugural (another first!) Australasian Bone & Joint Infection Conference in March before we had to become Zoom experts. It's testament to the ASID Office team and the SIGs for how quickly they were able to organise a series of fortnightly COVID-19 webinars.

Well done to the ASM Local Organising Committee who continued to work hard despite the setbacks and to the patience of members when the Zoonoses and NZ Sepsis conferences were postponed.

As the year went on, events were routinely held online but we had local hubs for certain meetings, such as the NZ conference and ANZPID clinical meeting.

Thanks to the subcommittees and SIGs (we now have six in total) that stepped up and ensured we had opportunities to connect and discuss relevant topics. Particular kudos to Aaron Bloch, Trainee Representative on Council who coordinated the formation of INTREPID as an online version of the Trainee Weekend, and which has proved very successful.

We held 14 Board Meetings (including eight teleconferences). We normally hold four formal Board meetings but this was no ordinary year and at the start of the pandemic the Board spoke regularly as things were moving so fast. It is important that the Board and Council understand and respond to members' needs, and I am honoured to work with such a talented group of office bearers who do just that. They have all been (like all members) extremely busy, and I'm grateful to them for keeping ASID front of mind.

A big thank you to the ASID office staff - Marilena, Maureen, Alison and Serena who seamlessly and efficiently managed everything from online meetings, webinars, media, and membership services at a time when the Society needed supporting more than ever. Early in 2021, Marilena Salvo left ASID after six years. We thank her for all her work and achievements with ASID during her time with us, and we wish her well in her new role with the Australian and New Zealand Society for Nephrology.

There is much discussion about the 'new normal'. ASID has proved that we can offer engaging events and discussion online, and we will continue to update our technology to continue meeting expectations and making the society even more relevant in the future.

Despite the disruptive year, ASID's financial performance was strong during 2020. It's proved that the Society can continue to operate even if unforeseen circumstances (like a pandemic!) disrupt the calendar of events and meetings. Our budget balance is outlined in more detail in the Treasurer's report.

As I write this message Australia has just commenced the COVID-19 vaccine rollout. It is testament to the hard work and dedication of our members who have found themselves on the frontline of Australia and New Zealand's response to the pandemic that we have got to this point.

Please continue to participate in our events, discussion forums, consider leadership positions and any other opportunities that come your way. Your ideas and participation is what drives ASID forward.

See the next few pages for details of **Events and Webinars**, **Advocacy**, **Member Communications**, and **Awards**.

Allen Cheng
ASID President

ASID Events and Webinars

Australasian Bone & Joint Infection Conference March 2020

The inaugural Australasian Bone & Joint Infection Conference (BJI) 2020 was held over two days in March 2020 in sunny Newcastle.

The BJI brought together orthopaedic surgeons, infectious diseases physicians, clinical microbiologists and trainees to discuss the latest developments in the prevention, diagnosis and management of bone and joint infections. Similar meetings are held regularly in Europe (EBJIS and OBIC) and are a very popular forum for cross-pollination of ideas between these disparate groups. Fostering connection and meaningful communication among these groups is vital to help improve outcomes from these devastating infections.

Event Snapshot

- 213 attendees.
- 19 speakers (9 Ortho/10 ID) including three international speakers.
- 25 abstracts were displayed as posters.
- 9 event sponsors.

The event featured international speakers such as Dr Craig J. Della Valle, Dr Simon Young and Dr Bridget Atkins. A highlight was a cement workshop in the exhibition hall. Congratulations to Dr Catherine McDougall, Orthopaedic Surgeon at Brisbane Orthopaedic Specialist Services who was awarded Best Infectious Diseases Poster, and to William McNamara, Junior Medical Officer at Royal Prince Alfred Hospital for Best Orthopaedic Poster.

We hope to hold another similar event in the future!

Extract from ASIDES May 2020.



*Dr David Dewar and
then ASID President Prof
Josh Davis*



*Declan Clausen Deputy Lord Mayor
Newcastle welcomes delegates.*



A packed house!



Bone cement workshop

ASID Events and Webinars

NZ Annual Meeting October 2020 First ASID hybrid meeting

The original NZ ASM 2020 planned alongside the NZ Sepsis Trust was postponed until November 2021 due to COVID-19. A smaller event was subsequently planned as a face-to-face event in Auckland. Due to a new unexpected outbreak of the virus in Auckland the event was changed to a hybrid meeting.

There were five hubs in total with Auckland the largest at Parnell Community Centre, a smaller Auckland hub at North Shore Hospital and hubs in Wellington, Christchurch and Midlands. Those who could not attend in person attended via ZOOM. Thank you to Chris Hopkins for putting together the program and convening the event.

We had 68 attend virtually and 79 were registered as face-to-face. A great turnout! We had a packed program of 20 speakers including two UK speakers (ASID Members), ASID President Allen Cheng, Ashleigh Bloomfield the NZ Director General of Health, Prof Michael Baker, the convenor, and proffered paper presenters. Ten abstracts were submitted with all being offered oral presentations. Congratulations to Dr Andrew Fox-Lewis, recipient of the ASID New Zealand Trainee Award.

Extract from NZ Report from Dr Nigel Raymond in ASIDES Dec 2020.

ANZPID Clinical Meeting October 2020

Featured presentations of clinical cases, engaging discussion, and the inaugural ID pub quiz.



2020 webinar snapshot

- **Nine** COVID-19 webinars with an **average of 111** attendees at each one. The highest attendance was a HICSIG webinar *COVID-19 Infection Prevention in Residential Aged Care Facilities* with **201** attendees.
- All SIGS hosted a COVID-19 webinar (some hosted two).
- **Eleven** ongoing webinars
- Introduction of INTREPID series with **average of 61** attendees at each one.
- **Five virtual hubs** as part of the hybrid NZ Annual Meeting.

ASID Events and Webinars

ASID was pleased to be one of the co-conveners of the **Special Edition - Australasian COVID-19 Virtual Conference** in December. ID physicians, public health professionals, scientists and researchers joined the event, a valuable opportunity to understand the challenges they faced in 2020, and take time out to think through the available science, discuss the approach to pandemic and disease management and look to the future.



- **435** registered participants
- Over **192** abstracts submitted
- **3** sponsors
- **3** virtual exhibitors (including ASID)

Spearheaded by Dr Aaron Bloch and the organising group, a series of fortnightly webinars commenced in October 2020 that aimed to not only replace the 2020 Trainee Weekend but to also become a regular fixture on the ASID educational calendar.

A few names were tossed around and thanks to Maureen from the ASID Office for coming up with **Introductory Trainee Education Program - Infectious Diseases**.

The team wasted no time in putting together a very successful program for 2020 - well done!

Some of the topics covered included *Vaccinology 1 - Introduction and Foundations*, *Vaccinology 2 - Special Populations and Troubleshooting*, *Working with the Microbiology Laboratory & an approach to interpretation of Microbiology Results*, and *Antibiotics for Multi-drug Resistant Bacterial Infections*.

[View Recordings.](#)

INTREPID

**Introductory
Trainee
Education
Program -
Infectious
Diseases**

Congratulations to our 2020 award recipients

Professor Deborah Williamson - The Frank Fenner Award for Advanced Research in Infectious Diseases

Professor Deborah Williamson is a Clinical and Public Health Microbiologist, Director of Microbiology at the Royal Melbourne Hospital, Deputy Director of the Microbiological Diagnostic Unit Public Health Laboratory at the Doherty Institute, and a laboratory head in the Department of Microbiology and Immunology at the University of Melbourne. She is Co-Head of Public Health at the Doherty Institute, and co-chair of the Communicable Diseases Genomics Network.




Dr Jimba Jatsho - John Forbes Travelling Nations Scholarship

Dr Jimba Jatsho, Pediatrician from Phuentsholing General Hospital Bhutan, will join us at the ASID Annual Scientific Meeting 2021. Dr Jatsho was invited by ASID member Dr Smathi Chong.



The **International Travel Award recipients** will be attending an international infectious diseases meeting of their choice when international travel becomes possible again.



Dr Victoria Hall
ID Registrar
The Alfred Hospital

Project:
Antimicrobial anaphylaxis: the changing face of severe antimicrobial allergy.



Dr Phoebe Williams
Paediatric Clinical Infectious Diseases Fellow
The Sydney Children's Hospital Network

Project: *The potential of fosfomycin for multi-drug resistant sepsis: An analysis of in vitro activity against invasive paediatric Gram-negative bacteria.*



Dr Eloise Williams
Microbiology Registrar
Royal Melbourne Hospital
Department of Infectious Diseases.

Project: *Nocardia bacteremia: a single-center retrospective review and systematic review of the literature.*

ASID Media and Advocacy in 2020

27 Nov: [ASID and ASHM: We need to avoid stigma and blame in our public health responses to COVID-19](#)

07 Oct: [ASID, ASA and ACIPC statement: Support for Australian Centre for Disease Control](#)

1 Sept: [ASID statement: Importance of ethically approved randomised clinical trials during COVID-19](#)

6 Aug: [Joint media statement: Protecting vulnerable populations against COVID-19 will help avoid second wave](#)

4 June: [Member of Govt's expert COVID-19 Working Group appointed President of the Australasian Society for Infectious Diseases](#)

18 May: [NZ ASID Statement on Level 2 restrictions](#)

24 March: [ASID letter to CMO on the use of hydroxychloroquine as prophylaxis against COVID-19](#)

20 March: [ASID protection of older and vulnerable Australians](#)

19 March: [ASID ACIPC Joint Statement: COVID-19 and detainees – recommendation for action](#)

5 Feb : [ASID first COVID-19 position statement](#)

ASID Member Communications

Weekly **eNews**

Quarterly **ASIDES**

Discussion forums: OzBug, Paediatrics, Trainees, NZbug, vaccsig-jab, and others.

More than **2,600 followers** on Twitter

Facebook **115 likes / 128 followers**



ASID was represented on different committees

Committee	Member	Appointed
ACSQHC Healthcare Infection Advisory Committee	Dr Andrew Stewardson	2017
ACSQHC Topic Working Group developing a clinical care standard on peripheral venous access	Dr Tony Allworth, A/Prof Archana Sud	Jan 2019
ASHM Contact Tracing Group website	Dr Ian Woolley	Oct 2020
ASHM HBV Clinical Standards and Accreditation Panel (CSAP)	A/Prof Gail Matthews	May 2019
Aust DoH Remdesivir Release Advisory Panel	Prof Josh Davis	July 2020
Australian Prescriber Journal	Dr Ashley Watson	
Aust. Red Cross Microbiome Clinical Advisory Board	Dr Laurens Manning	Nov 2019
Australian STI Management Guidelines Major Review Reference Committee	Dr Anna Pierce	Aug 2020
Australian Strategic and Technical Advisory Group on Antimicrobial Resistance (ASTAG)	Prof Allen Cheng	
Choosing Wisely Australia	Dr Brendan McMullan	2019
Communicable Diseases Network of Australia (CDNA)	Dr Katherine Gibney	July 2018-July 2021
Communicable Diseases Intelligence Editorial Advisory Committee	Prof Mark Ferson	Sept 2015
COVID-19 Clinical Evidence Taskforce Steering Committee	Dr Joseph Doyle, Dr Brendan McMullan	March 2020
Internal Medicine Journal Editorial Committee	Dr Ian Woolley	May 2017
Nat Clin Taskforce to review Nat Safety and Quality Healthcare Service Standard on Preventing and Controlling HAIs	Dr Kate Clezy	Oct 2020
NIPCEG (New Zealand)	Dr Joshua Freeman, Dr Matthew Kelly	Oct 2020
NZ Health Antimicrobial Resistance Coordination (HARC)	Dr Susan Morpeth	Nov 2019
RACP Adult Medicine Division Council	Prof Joshua Davis	
RACP Infectious Diseases JSAC	Prof Joshua Davis	
RACP New Zealand Adult Medicine Division Committee	Dr James Taylor	
RACP COVID-19 Working Group	Dr Tony Allworth	
VICNISS Healthcare Associated Infection Surveillance Coordinating Centre Advisory Committee	Dr Andrew Stewardson	March 2017
Victorian HIV and Viral Hep Training and Learning (VHHITAL) Expert Reference Panel	Dr Joseph Doyle	April 2017
WSPID Executive Committee	A/Prof Penelope Bryant	2017
WSPID Educational Committee	Dr Tony Walls	2017

ASID is now a recognised charity

Australasia needs a strong pipeline of leaders in infectious diseases research to help protect future generations. Now, more than ever before, people are counting on the field of ID to predict, prevent and treat those affected every day.

ASID became a registered charity in Australia and New Zealand in 2020 and is now accepting donations so we can continue to offer things like more research grants.

Thanks to the Fundraising Working Group for getting this up and running. **[Read more.](#)**



Honorary Treasurer’s Report

Dr Joseph Doyle



ASID ended 2020 with a cash surplus of \$57,116. Much of ASID’s surplus income comes from conferences and meetings, so being forced to cancel two of our major events (ASM and Zoonoses) did have some financial impact. In the year prior (2019) ASID had a particularly strong surplus from sponsorship of events. For keen readers of the financial accounts, it is worth noting that ASID paid a deposit for the ASM Melbourne venue which was returned in full in early 2021 (hence it is not visible in the 2020 accounts reported here). Overall, given the disruption COVID-19 caused in 2020 we are in a good financial position for the year ahead. See [Audited Financial Report 2020](#).

The Board is conscious to be using funds wisely, and not retaining surplus funds more than is necessary. In 2020, we awarded a \$25,000 research grant for the first time. This is something the ASID Board is strongly committed to and we’re pleased to be offering this grant on a sustainable basis. Other research support initiatives can now be considered because of the returns on our invested funds.

Over the past few years, we have also moved events management in-house. That has allowed us to train and develop our own staff and capacity, and reduce expenses on external contractors. I was very proud of the way the SIGS (supported by the ASID office team) organised themselves to conduct COVID-19 webinars. Having our events team in-house meant that we could move from face-to-face events to webinars very easily.

We are now a registered charity in Australia and New Zealand. A fundraising committee has been established to help the Society to look at ways of opening up additional fundraising streams over the coming year. I would like to thank the Finance Committee (Sharon Chen, Krispin Hajkowicz, David Looke and Pat Charles) and the ASID office team for their support and advice in 2020.

Membership Fees for 2020

Membership Fees	Australian Members	New Zealand and overseas members
Full	\$330	\$290
Associate	\$125	\$105
Retired	\$35	\$30

Honorary Secretary's Report

A/Prof Katie Flanagan



I would like to welcome all new Full and Associate ASID Members who joined during 2020, and to thank all our ongoing Members for their continued support during what was an incredibly challenging year.

The Society is in a strong position with more than 1000 members and increasing, cementing ASID's relevance in the infectious disease and microbiology sectors.

We aim to continue to provide value to our members, and at a time when sharing information (and providing support) was critical I'm delighted that ASID was able to rise to the online communication challenge. We plan to continue to expand on the services, activities and research opportunities we offer throughout 2021, much via online due to the ongoing COVID-19 constraints.

Membership Data

Members 1 Jan - 31 Dec 2020	
Full	601
Associate	408
Retired	27
Honorary/Life	33
TOTAL	1069

New Associate Members 2020

NAME	STATE	PROPOSED/SECONDED	DATE
Chaw Aye	QLD	R Horvath/R Norton	8/01/2020
Jaimie Frazer	QLD	P Chapman/A Redmond	11/01/2020
John Vardanega	QLD	D Looke/M Sehu	13/01/2020
Varsha Sivalingam	NSW	Hong Foo/John Ng	13/01/2020
Adele Batrouney	VIC	J Trubiano/A Mahony	13/01/2020
Michael Osthoff	Swiss	Roy Chean/BenTeh	13/01/2020
Sudharsan Venkatesan	NT	E Spencer/E Meuman	31/01/2020
Anna Watson	NT	S Janson/C Marshall	29/01/2020
Mohammed Issa	NZ	J Green/G Mills	27/01/2020
Michelle Sam	NZ	E Best/L Voss	30/01/2020
Bianca Graves	QLD	S Janson/E Meumann	9/02/2020
Jeffrey Masters	NSW	D Andresen/D Marriott	10/02/2020
Shu Ki Tsoi	VIC	A Steer/J Osowicki	10/02/2020
Aadith Ashok	VIC	A Jenney/L Einsiedel	17/02/2020
Sarah Cranney	QLD	A Chaudhuri/R Horvath	17/02/2020
Kylie D'Arcy-Evans	VIC	J Lau/U Devi	17/02/2020

New Associate Members 2020

NAME	STATE	PROPOSED/SECONDED	DATE
Siobhan Hurley	NSW	J Post/K Overton	17/02/2020
Cheryn Palmer	QLD	D Looke/M Sehu	17/02/2020
Erasmus Smit	NZ	J Elvy/V Sathyendran	17/02/2020
Monika Bolger	QLD	K Alcorn/A Jones	18/02/2020
Pauline Megallaa	VIC	K Langan/M Kainor	18/02/2020
Sonia Koning	VIC	J Lau/ U Devi	2/03/2020
Jenna Beaumont	NZ	S Morpeth/G Walls	9/03/2020
Maurizio Stefani	NSW	V Nagrendra/ J Ng	9/03/2020
Maxwell Braddick	QLD	C Heather/K Oman	9/03/2020
Tom Hills	NZ	R Lane/M Hobbs	16/03/2020
Shayne Camilleri	NT	A K Aung/M Loftus	16/03/2020
Mirvat Said	NSW	P Palasanthiran/B McMullan	16/03/2020
Grace Butel-Simoes	VIC	T Korman/C Dendle	26/03/2020
Linda Mayer	NSW	R Mailk/P Newton	26/03/2020
Michelle Scoullar	VIC	S Majumdar/J Richards	26/03/2020
Fiona Clarke	VIC	J Daffy/J Darby	26/03/2020

New Associate Members 2020

NAME	STATE	PROPOSED/SECONDED	DATE
Jenny Firman	ACT	Gary Lum & Allen Cheng	31/03/2020
Greg Fox	NSW	Ben Marais & Emma McBryde	31/03/2020
Arran Painter	NSW	A Sud/J Brown	31/03/2020
Ian Seppelt	NSW	A Sud/J Brown	31/03/2020
Joseph Ischia	VIC	A Street/S Tong	4/04/2020
Shidan Tosif	VIC	N Crawford/F Russell	4/04/2020
Nila Dharan	NSW	D Marriot/Matthews	9/04/2020
Gary Nicholls	NSW	D Marriot/J Harkness	9/04/2020
Emma Louise Smith	VIC	J Davies/C Boutlis	17/04/2020
Sahra Ashley	QLD	T Yarwood/D Stefanski	17/04/2020
Mihiri Weerasuria	VIC	J McMahon/A Fuller	28/04/2020
Scott Abbinga	VIC	D Spelman/A Jenney	28/04/2020
Lawrence Huang	QLD	N Runnegar/E Bursle	11/05/2020
Alison Pickering	QLD	J Clark/A Irwin	25/05/2020
Phillipa Edmiston	WA	A Bowen/C Blythe	25/05/2020

New Associate Members 2020

NAME	STATE	PROPOSED/SECONDED	DATE
Caroline Banh	NSW	S Sivagnanam/M Martinello	28/05/2020
Matthew Tweedale	SA	Ashley Watson & Heather Wilson	4/06/2020
Gary Smith	SA	Morgyn Warner & Ivan Bastian	9/06/2020
Nupur Goyal	VIC	Lyn-Li Lim & Carolyn Beckett	9/06/2020
Lucy Deng	NSW	Kristine Macartney & Archana Koirala	16/06/2020
Sandra Steele	NSW	Steve Muhi & Jacqui Norris	18/06/2020
Darcy Gray	NSW	Omar Shum & Simeon Crawford	18/06/2020
Andrew Farrington	VIC	Sarah Boyd & Alexandra Stewart	22/06/2020
Georgia McCluskey	VIC	Mary Jo Waters & Amy Crowe	6/07/2020
Duncan Campbell	VIC	Jonathan Darby & Steve Muhi	6/07/2020
Nicola Sweeney	UK	Emily Tucker & Catherine McGregor	23/07/2020
Niall Johnston	NSW	John Ferguson & Josh Davis	23/07/2020
Samantha Bannister	VIC	Joshua Osowicki & Nigel Curtis	10/08/2020
Ana Domazetovska	NSW	Hong Foo & Michael Maley	17/08/2020
Martin Hansen	NT	Ella Meumann & Sonja Janson	24/08/2020

New Associate Members 2020

NAME	STATE	PROPOSED/SECONDED	DATE
Steven McAuley	NZ	Nigel Raymond & Tim Blackmore	1/09/2020
Jessica O'Keeffe	VIC	Eugene Athan & Daniel O'Brien	3/09/2020
Holly Jordan	NSW	Josh Davis & Mark Loewenthal	17/09/2020
Cate Coffey	NT	Daniel O'Brien & Lloyd Einsiedel	28/09/2020
Sarah Allen	SA	Brett Ritchie & Nan Vasilunas	28/09/2020
Myung Seo Ko	NSW	Pam Konecny & Chris Weatherall	28/09/2020
Nicholas Betts	NSW	Sarah Coghill & Elaine Cheong	7/10/2020
Mehrab E Hossain	VIC	Raquel Cowan & Robert Commons	7/10/2020
Caitlyn Sun	SA	David Gordon & Emily Rowe	15/10/2020
Maya Wositzky	SA	Jared Green & Paul Huggan	9/11/2020
Thomas Wong	NZ	Jared Green & Paul Huggan	9/11/2020
Tran Nguyen	NSW	Pamela Palasanthiran & Brendan McMullan	9/11/2020
Matthew Palladino	WA	Asha Bowen & Daniel Yeoh	4/12/2020

New Full Members 2020

NAME	STATE	PROPOSED/SECONDED	DATE
Brett Ritchie	SA	C Cooper/N Vasilunas	13/01/2020
Claire Dendle	VIC	I Wolley/B Rogers	11/01/2020
Sonja Janson	NT	J Davies/C Marshall	7/01/2020
Alison Winning	NSW	S Appleton/M Sehu	29/01/2020
Catherine Marshall	VIC	U Devi/C Beckett	17/02/2020
Hemalatha Varadhan	NSW	M Loewenthal/J Davis	24/02/2020
Melanie-Anne John	NSW	A Hofmeyr/L Noonan	24/02/2020
Benjamin Clark	WA	J Dyer/M Wilson	2/03/2020
Astrid Arellano	WA	M Beaman/S Bowen	16/03/2020
Simon Briggs	NZ	M Nisbet/M Hobbs	16/03/2020
Daniel Stefanski	VIC	T Yarwood/E Binotto	16/03/2020
Jonathan Chambers	WA	D Chih/C Italiano	19/03/2020
Ohide Otome	WA	A Langlands/E Woolnough	19/03/2020
Ruth Zadoks	NSW	J Torresi/P Kelley	26/03/2020
Lucy Somerville	NSW	J Brown/M Martinello	26/03/2020
Alex Tai	VIC	J Torresi/P Kelley	26/03/2020

New Full Members 2020

NAME	STATE	PROPOSED/SECONDED	DATE
Katherine Kociuba	NSW	J Ng/A Hofmeyr	26/03/2020
Julian Elliott	VIC	J Davis/A Cheng	26/03/2020
Catherine Streeton	VIC	S Garland/M Starr	30/03/2020
Mark Beale	QLD	D Looke/K Daveson	31/03/2020
Timothy Gilbey	NSW	M O'Sullivan/J Iredell	31/03/2020
Joe Sasadeusz	VIC	A Street/P Johnson	4/04/2020
Angie Pinto	NSW	R Davis/A Lee	4/04/2020
James Branley	NSW	J Brown/Z Jennings	9/04/2020
Sudha Pottumarthu Boddu	WA	S Chong/S Ketharanathan	21/04/2020
Margie Danchin	VIC	A Steer/J Ozowicki	5/05/2020
Rebecca Traub	VIC	S Muhi/H Sheorey	28/05/2020
Richard Bradbury	VIC	Steve Muhi & Harsha Sheorey	30/06/2020
Donald Packham	NSW	Pam Konecny & Chris Weatherwall	17/08/2020
Philip Russo	VIC	Andrew Stewardson & Allen Cheng	21/09/2020

New LMIC Members 2020


One Associate Member joined in February 2020

Congratulations to all Members admitted to FRACP in 2020

Tim Whitmore
Lucy Attwood
Belinda Bin Lin
Georgina Trotter
Jim Stewart
Emma Tippet
Brad Gardiner
Victor Au Yeung
Jared Green
Jacob Williams
David Turner
Ian Wong
Elizabeth Catchpoole
Alexandra Stewart
Kevin O'Callaghan


Members snapshot 2020

New Members Comparison 2007-2019




ASID Membership by Location

OS incl NZ 145
AC T 21
NSW 251
NT29
QLD 141
SA63
TAS 16
VIC 313
WA 90
Total 1069



Special Interest Groups 2020



Special Interest Groups 2020

The Australian and New Zealand Mycoses Interest Group (ANZMIG) promotes excellence in clinical and laboratory mycology through collaborative clinical and translational research focussed on improving patient-centred outcomes.	Co-Chair Karina Kennedy Co-Chair Orla Morrissey (replaced by Celia Cooper at the end of 2020). Secretary Sarah Kidd Scientific Chair Chris Heath, Ian Arthur, Debbie Marriott Working Group Chairs Monica Slavin/Sharon Chen Trainee Representative Blake Nield
The Australia and New Zealand Paediatric ID Group (ANZPID) promotes children's health in the field of paediatric infectious diseases.	Chair Asha Bowen Deputy Chair Emma Best Committee Members Christopher Blyth, Archana Koirala, Nan Vasilunas, Anita Campbell Trainee Committee Member David Foley Research Committee Member Tony Walls
The Hospital Infection Control Special Interest Group (HICSIG) provides a forum for members that have clinical and/or research interests in infection prevention & control and/or antimicrobial stewardship.	Chair Andrew Stewardson Deputy Chair Caroline Marshall Committee Members Rhonda Stuart, Rebecca McCann, Deb Friedman, Trish Ferguson, Paul Griffin, Andie Lee, Jason Kwong.
The Vaccination Special Interest Group (VACSIG) acts as a focal point bringing together the many people working in the area of vaccination.	Chair Katie Flanagan Committee Members Michelle Giles, Nigel Crawford, Fiona Russell, Emma Best, Archana Koirala, Sophie Wen, Ben Teh.

Special Interest Groups 2020

The Viral Hepatitis Special Interest Group (VHSIG) provides a forum for ASID members that have clinical and/or research interests in viral hepatitis.	Chair Joseph Doyle, Past Chair Mark Douglas Deputy Chair Jane Davies Committee Members Jenny Hoy, Gail Matthews Sushena Krishnaswamy, Alison Ratcliff. Trainee Representative Naomi Whyler ASHM Representative Sami Stewart
The Zoonoses Special Interest Group (ZOOSIG) brings together expertise on zoonoses, and the intersection between animal health, human health and agriculture.	Co-Chair David Looke Co-Chair Rowland Cobbold Committee Members Katrina Bosward, Richard Bradbury, Bart Currie, Jane Dyer, Stephen Muhi, Jenny Robson, Harsha Sheorey, Kathryn Wilks.
The Clinical Research Network (CRN) is a group of infectious diseases physicians interested in facilitating high quality, multi-centre, investigator-initiated studies.	Chair Steven Tong Deputy Chair Asha Bowen Members Tony Walls, Anna Ralph, Andrew Stewardson, Joseph Doyle, Gail Matthews, Damon Eisen. Trainee Representative Shu Jin Tan Leaders of the Working Groups David Paterson, Josh Davis, Rob Commons.
ASID New Zealand	Chair Nigel Raymond Treasurer Arthur Morris Webmaster/NZBUG Moderator Richard Everts Trainee Representative Nic Young NZ AM Organiser Chris Hopkins Committee Members Emma Best, Sarah Metcalf, Kerry Read, Kate Grimwade.



Australasian Society for Infectious Diseases (ASID) Ltd.
Suite 302, Level 3
478 George Street
Sydney NSW 2000

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD
A COMPANY LIMITED BY GUARANTEE

A.B.N. 20 108 151 093

FINANCIAL REPORT

FOR THE PERIOD ENDED 31 DECEMBER 2020

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

DIRECTORS' REPORT

Your directors present their report on the company for the period ended 31 December 2020.

DIRECTORS

The names of the directors in office at any time during or since the end of the year are:

Prof J Davis
Prof A Cheng
Dr B McMullan
Prof K Flanagan

Dr J Doyle
A/Prof P Charles
Dr J Clark (appointed April 2019)

The directors have been in office since the start of the financial period to the date of this report unless otherwise stated.

OPERATING RESULTS

The company produced a net profit for the financial year amounting to \$ 57,116 (2019 profit: \$263,076).

REVIEW OF OPERATIONS

A review of the operations of the company during the financial year and the results of those operations are as follows:

- The principal activity of the company during the financial year was to cultivate and promote interest and support in the field of medicine for infectious diseases.
- No significant change in the nature of these activities occurred during the financial year.
- The company was incorporated on 14 September 2018 to take over the operations of the Australasian Society for Infectious Diseases Inc.

MISSION/PURPOSE

The Society is a charitable institution that exists to provide a range of services and support for promoting the treatment and control of infectious diseases and medical conditions, disorders and ailments arising directly from infectious diseases and the consequent impact that infectious disease can have on human health generally, on specific diseases, on public safety, productivity and quality of life generally.

GOALS

Promoting and advancing knowledge and education in all areas of the science and clinical practice of the fields of infectious diseases, clinical microbiology and associated syndromes and ailments;

Convening regular scientific meetings and arranging other research and educational seminars and conferences on infection-related topics in the Australasian region including topics covering the affairs, interest and duties of members of the medical and related health professions and others engaged in the practice, study and control of infectious diseases;

Encouraging and facilitating clinical and laboratory research in the field of infectious diseases;

Awarding research grants from the funds of the Society and establishing scholarships, prizes or awards in such manner as the Board may determine

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

DIRECTORS' REPORT (Continued)

Engaging with government, agencies and departments to guide and support policy development for the management and control of infectious diseases and antimicrobial resistance;

Facilitating communication between groups and individuals who have an interest in some aspect of infectious disease study, management and control and encouraging professional relationships and understanding of Members;

Cooperating with or advising other bodies interested in infectious disease study, treatment, management and control and infectious disease science and communicating with similar organisations in Australia and other parts of the world;

Encouraging public and professional education about the causes and treatment of infectious diseases;

KEY PERFORMANCE MEASURES

The company measures its performance on the basis of sound financial results through prudent management of limited resources and the promotion of research into infectious diseases. The longer term measurement of this success is seen in better patient outcomes for the general public.

EVENTS SUBSEQUENT TO BALANCE DATE

No matters or circumstances have arisen since the end of the financial year which have significantly affected or may significantly affect the operations of the company, the results of those operations, or the state of affairs of the company in future financial years.

LIKELY DEVELOPMENTS

There are no likely developments in the operations of the company, which are expected to affect the results of the company's operations in subsequent financial years.

ENVIRONMENTAL ISSUES

The company's operations are not regulated by any significant environmental regulation under a law of the Commonwealth or of a State or Territory.

DIVIDENDS

The company is limited by guarantee and the Constitution does not permit the distribution of dividends to its members.

No dividends have been paid, declared or proposed by the company since the commencement of the financial year.

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

DIRECTORS' REPORT (Continued)

DIRECTORS' BENEFITS

Since the commencement of the financial year no director of the company has received or become entitled to receive, a benefit because of a contract that the director, a firm of which the director is a member, or an entity in which the director has a substantial financial interest, has made with:

- The company, or
- An entity that the company controlled or a body corporate that was related to the company, when the contract was made or when the director received, or became entitled to receive, the benefit.

OPTIONS

The company does not have a share capital as it is a company limited by guarantee. Accordingly, no options over interests in the company were granted during or since the end of the financial year and there were no options outstanding at the date of this report.

INSURANCE OF OFFICERS

During the financial year, the Company did not pay a premium to insure certain officers of the company, details of the nature of the cover and premium paid are prohibited from disclosure in accordance with the terms and conditions of the policy.

PROCEEDINGS ON BEHALF OF THE COMPANY

No person has applied for leave of Court to bring proceedings on behalf of the company or intervene in any proceedings to which the company is party for the purpose of taking responsibility on behalf of the company for all or any part of those proceedings.

The company was not a party to any such proceedings during the year.

DIRECTORS MEETINGS

During the period 31 December 2020, six meetings of the company's directors was held.

For each director, particulars of the relevant numbers of meetings held and attended during the period of directorship are shown below:

Director	Meetings Eligible To Attend	Meetings Attended
	Executive	Executive
Prof J Davis	6	6
Prof A Cheng	6	6
Dr J Doyle	6	6
Prof K Flanagan	6	5
Dr B McMullan	6	6
Dr J Clark	6	6
A/Prof P Charles	6	6

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

DIRECTORS' REPORT (Continued)

DIRECTORS QUALIFICATIONS

Particulars of the directors' experience and special responsibilities (if any) of each director of the company who held office during or since the end of the financial year are:

DIRECTOR	RESPONSIBILITIES / EXPERIENCE
Prof Joshua Davis	Practising consultant (John Hunter Hospital) FRACP (2005) MBBS (1994) PhD (2011). In May 2018 elected to the Council of the Australasian Society for Infectious Diseases Inc to the position of President. On Council since 2010.
Prof Allen Cheng	Practising physician (Alfred Health) MBBS (1993), FRACP (2002) PhD (2005), MPH (2007), MBIostat (2014), GAICD (2017) In May 2018 elected to the Council of the Australasian Society for Infectious Diseases Inc to the position of Vice President. On Council since 2013.
Dr Joseph Doyle	Practising consultant in Melbourne, MBBS 2002, MPH 2006, FRACP 2011, FAFPHM 2014, PhD 2015. Elected to Council of ASID in April 2016, Deputy Chair of Viral Hepatitis Special Interest Group in March 2017, and Chair of Finance Committee in August 2018.
Dr Brendan McMullan	Practising consultant (Sydney Children's Hospital); FRACP 2012; FRCPA 2012; BMed(Hons) 2001. (Elected to Council in May 2018)
Prof Katie Flanagan	Practising consultant (Launceston General Hospital, Tasmania) MBBS (1992) DTM&H (1994) PhD (2000) CCST (2004) FRCP(UK) (2009) FRACP (2013). In 2017 elected to the Council of the Australasian Society for Infectious Diseases Inc to the position of Honorary Secretary. On Council since 2013.
A/Prof Patrick Charles	Practising consultant at Austin Health in Heidelberg, Victoria. MBBS from the University of Melbourne in 1995. FRACP 2003. PhD from the University of Melbourne in 2008. Elected to the ASID Council in March 2015
A/Prof Julia Clark	Director of Infectious diseases/Immunology/Rheumatology at Queensland Children's Hospital. On various ASID committees since 2012. Her clinical experience encompasses Infectious Disease/Immunology training and consultant experience in the UK, from developing and delivering national ID training programmes to leading and managing an Infection Management Service in Queensland.

The company is registered with the Australian Securities and Investments Commission as well as the Australian Charities and Not-for-profit Commission and is a company limited by guarantee. If the company is wound up, the constitution states that each member is required to contribute a maximum of \$1.00 each towards meeting any outstanding obligations of the entity. At 31 December 2020, the total amount that members of the company are liable to contribute if the company is wound up is \$1,069.00

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out on page 7.

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

DIRECTORS' REPORT (Continued)

Signed in accordance with a resolution of the Board of Directors:

Director:  Joseph Doyle

Dated this 1 day of March 2021

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

**AUDITOR'S INDEPENDENCE DECLARATION
UNDER SECTION 60-40C OF AUSTRALIAN CHARITIES AND NOT-FOR PROFIT COMMISSION ACT
2012**

In accordance with Subdivision 60-C of the Australian Charities and Not-for-profit Commission Act 2012, I am pleased to provide the following declaration of independence to the directors of Australasian Society for Infectious Diseases Ltd.

I declare that, to the best of my knowledge and belief, during the period ended 31 December 2020 there has been:

- (i) no contraventions of the auditor's independence requirements as set out in the Australian Charities and Not-for-profit Commission Act 2012 in relation to the audit; and
- (ii) no contraventions of any applicable code of professional conduct in relation to the audit.

**MARK TINWORTH
CHARTERED ACCOUNTANT**



North Sydney,



TINWORTH & Co

CHARTERED ACCOUNTANTS and BUSINESS ADVISORS

INDEPENDENT AUDIT REPORT TO THE MEMBERS OF AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

Opinion

We have audited the attached financial report of Australasian Society for Infectious Diseases Ltd ("the entity") which comprises the statement of financial position as at 31 December 2020, the statement of profit or loss and other comprehensive income, statement of recognised income and expenditure, cash flow statement for the period then ended, and notes to the financial statements, including a summary of significant accounting policies, other explanatory notes and the Directors' Report.

In our opinion, the accompanying financial report of Australasian Society for Infectious Diseases Ltd is in accordance with Division 60 of the Australian Charities and Not-for-profit Commission Act 2012, including:

1. giving a true and fair view of the Company's financial position as at 31 December 2020 and of its financial performance for the period then ended; and
2. complying with Australian Accounting Standards, and Division 60 of the Australian Charities and Not-for-profit Commission Act 2012.

Basis for Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Directors in accordance with the auditor independence requirements of the ACNC Act 2012 and the ethical requirements of the Accounting Professional and Ethical Standard Board's APES 110: *Code of Ethics for Professional Accountants* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of the Directors for the financial report

The directors are responsible for the preparation and fair presentation of the financial report that gives a true and fair view and have determined the basis of preparation described in Note 1 to the financial report is appropriate to meet the requirements of the ACNC Act and is appropriate to meet the needs of the members. The directors' responsibility also includes such internal control as the directors determine is necessary to enable the preparation of a financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.


WWW.TINWORTH.COM

LEVEL 2, 66 BERRY ST NORTH SYDNEY NSW 2060 | P (02) 9922 4644 | F (02) 9959 3642 | ABN 43 624 513 140

Liability limited by a scheme approved under Professional Standards Legislation

- Identify and assess the risks of material misstatements of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis of our opinion. The risk of not detecting material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Committee's internal control
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the company's use of going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion.
- Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieved fair representation.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



MARK TINWORTH
CHARTERED ACCOUNTANT

North Sydney

1/March 2021

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

DIRECTORS' DECLARATION

The directors of the company declare that:

1. The financial statements and notes, as set out on pages 11 to 27 are in accordance with the requirements of the Australian Charities and Not-for-profit Commission Act 2012 and:
 - (a) comply with Australian Accounting Standards applicable to the entity; and
 - (b) give a true and fair view of the company's financial position as at 31 December 2020 and of its performance for the period ended on that date of the company.
2. In the directors' opinion there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

This declaration is signed in accordance with subs 60.15(2) of the Australian Charities and Not-for-profit Commission Regulation 2013.

Director:



Dated this 1 day of March 2021

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

STATEMENT OF COMPREHENSIVE INCOME FOR THE PERIOD ENDED 31 DECEMBER 2020

	Note	2020 \$	2019 \$
Revenues	2	506,081	1,227,747
Employee benefits expense		(224,769)	(186,135)
Depreciation expenses		(897)	(897)
Conference expenses		(87,713)	(430,231)
Special interest group expenses		(27,572)	(213,912)
Administration expenses		<u>(108,013)</u>	<u>(133,496)</u>
Profit (loss) before income tax	3	57,116	263,076
Income tax expense	1	<u>-</u>	<u>-</u>
Profit after income tax		57,116	263,076
Other comprehensive income after income tax		<u>-</u>	<u>-</u>
Total comprehensive income for the year		<u>-</u>	<u>-</u>
Total comprehensive income attributable to members of the entity		<u>57,116</u>	<u>263,076</u>

The accompanying notes form part of these financial statements

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

STATEMENT OF FINANCIAL POSITION AS AT 31 DECEMBER 2020

	Note	2020 \$	2019 \$
CURRENT ASSETS			
Cash and cash equivalents	4	2,076,645	2,025,537
Other assets	5	<u>86,788</u>	<u>76,376</u>
TOTAL CURRENT ASSETS		<u>2,163,433</u>	<u>2,101,913</u>
NON-CURRENT ASSETS			
Property, plant and equipment	6	<u>1,817</u>	<u>2,714</u>
TOTAL NON-CURRENT ASSETS		<u>1,817</u>	<u>2,714</u>
TOTAL ASSETS		<u>2,165,250</u>	<u>2,104,627</u>
CURRENT LIABILITIES			
Trade and other payables	7	56,864	60,486
Short term provisions	8	<u>24,205</u>	<u>17,076</u>
TOTAL CURRENT LIABILITIES		<u>81,069</u>	<u>77,562</u>
TOTAL LIABILITIES		<u>81,069</u>	<u>77,562</u>
NET ASSETS		<u>2,084,181</u>	<u>2,027,065</u>
EQUITY			
Retained Earnings		<u>2,084,181</u>	<u>2,027,065</u>
TOTAL EQUITY		<u>2,084,181</u>	<u>2,027,065</u>

The accompanying notes form part of these financial statements

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

**STATEMENT OF RECOGNISED INCOME AND EXPENDITURE
FOR THE PERIOD ENDED 31 DECEMBER 2020**

	Retained Earnings
	\$
Balance 1 January 2019	2,027,065
Profit (Loss) for the 2020 year	<u>57,116</u>
Balance as at 31 December 2020	<u>2,084,181</u>

The accompanying notes form part of these financial statements.

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

**STATEMENT OF CASH FLOWS
FOR THE PERIOD ENDED 31 DECEMBER 2020**

	Note	2020 \$	2019 \$
CASH FLOWS FROM OPERATING ACTIVITIES			
Members' & Customers' Receipts		495,728	1,213,508
Interest Received		16,290	11,967
Payments to Suppliers & Donations		<u>(460,910)</u>	<u>(951,719)</u>
Net Cash Generated from Operating Activities	11	<u>51,108</u>	<u>273,756</u>
Net Increase (Decrease) in Cash Held		51,108	273,756
Cash at the Beginning of The Financial Year		<u>2,025,537</u>	<u>1,751,780</u>
Cash at the End of the Financial Year	4	<u>2,076,645</u>	<u>2,025,537</u>

The accompanying notes form part of these financial statements.

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2020

1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

This general purpose financial report has been prepared in accordance with the Australian Charities and Not-for-profit Commission Act 2012 and Australian Accounting Standards and Interpretation of the Australian Accounting Standards Board. The company is a not-for-profit entity for financial reporting purposes under Australian Accounting Standards. Material accounting policies adopted in the preparation of this financial report are presented below and have been consistently applied unless otherwise stated. The Australasian Society for Infectious Diseases Ltd is an individual entity, incorporated and domiciled in Australia. Australasian Society for Infectious Diseases Ltd is a company limited by guarantee.

The financial report, except for the cash flow information, has been prepared on an accruals basis and is based on historic costs, modified, where applicable by the measurement at fair value of selected non-current assets, financial assets and financial liabilities. The amounts presented in the financial report have been rounded to the nearest dollar.

Income Tax

No provision for income tax has been raised as the entity is exempt from income tax under Division 50 of the Income Tax Assessment Act 1997.

Financial Instruments

Initial recognition and measurement

Financial assets, comprising trade and other receivables, cash and cash equivalents, financial assets and trade and other payables, are initially measured at fair value on trade date, which includes transaction costs, when the related contractual rights or obligations exist except where the instrument is classified at fair value through profit & loss in which case transaction costs are expensed to profit & loss immediately.

Classification and subsequent measurement

Financial instruments are subsequently measured at either fair value, amortised cost using the effective interest rate method or cost. Fair value represents the amount for which an asset could be exchanged or a liability settled, between knowledgeable, willing parties. Where available, quoted prices in an active market are used to determine fair value. In other circumstances, valuation techniques are adopted. Amortised cost is calculated as:

- 1 the amount at which the financial asset or financial liability is measured at initial recognition;
- 2 less principal repayments;
- 3 plus or minus the cumulative amortisation of the difference, if any, between the amount initially recognized and the maturity amount calculated using the effective interest method; and
- 4 less any reduction for impairment.

The effective interest rate method is used to allocate interest income or interest expense over the relevant period and is equivalent to the rate that exactly discounts estimated future cash payments or receipts (including fees, transaction costs and other premiums or discounts) through the expected life (or when this cannot be reliably predicted, the contractual term) of the financial instrument to the net carrying amount of the financial asset or financial liability. Revisions to expected future net cash flows will necessitate an adjustment to the carrying value with a consequential recognition of an income or expense in profit or loss.

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2020

1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

Financial assets at fair value through profit & loss

Financial assets are classified at fair value through profit or loss when they are held for trading for the purpose of short term profit taking, or when they are derivatives not held for hedging purposes, or when they are designated as such to avoid an accounting mismatch or to enable performance evaluation where a group of financial assets is managed by key management personnel on a fair value basis in accordance with a documented risk management strategy. Such assets are subsequently measured at fair value with changes in carrying value included in profit or loss.

Financial liabilities

Non-derivative financial liabilities (excluding financial guarantees) are subsequently measured at amortised cost.

Fair value

Fair value is determined based on current bid prices for all quoted investments. Valuation techniques are applied to determine the fair value for all unlisted securities, including recent arm's length transactions, reference to similar instruments and option pricing models.

Impairment

At each reporting date, the board assesses whether there is objective evidence that a financial instrument has been impaired. In the case of available-for-sale financial instruments, a prolonged decline in the value of the instrument is considered to determine whether impairment has arisen. Impairment losses are recognised in the statement of comprehensive income.

Impairment of Assets

At each reporting date, the board reviews the carrying values of its tangible and intangible assets to determine whether there is any indication that those assets have been impaired. If such an indication exists, the recoverable amount of the asset, being the higher of the asset's fair value less cost to sell and value in use, is compared to the asset's carrying value.

Any excess of the asset's carrying value over its recoverable amount is expensed to the statement of comprehensive income.

De-recognition

Financial assets are de-recognised where the contractual right to receipt of cash flows expires or the asset is transferred to another party whereby the entity no longer has any significant continuing involvement in the risks and benefits associated with the asset. Financial liabilities are de-recognised where the related obligations are either discharged, cancelled or expire.

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2020

1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

The difference between the carrying value of the financial liability extinguished or transferred to another party and their fair value of consideration paid, including the transfer of non-cash assets or liabilities assumed, is recognised in profit or loss.

Depreciation of Plant and Equipment

Each class of property plant and equipment is carried at cost or fair value less, where applicable, any accumulated depreciation.

Plant and equipment are measured on the cost basis. All assets are depreciated using the straight line basis so as to write off the cost of each asset over its expected useful life to the company.

Depreciation rates used for each class of asset are:

Class of fixed asset	Depreciation rate
Plant and Equipment	10.0%
Fixtures and Fittings	12.5%

An asset carrying amount is written down immediately to its recoverable amount if the assets carrying amount is greater than its estimated recoverable amount.

Gains and losses on disposal are determined by comparing proceeds with the carrying amount. These gains and losses are included in the statement of comprehensive income. When revalued assets are sold, amounts included in the revaluation reserve relating to that asset are transferred to retained earnings.

Lease payments are allocated between the reduction of the lease liability and the lease interest expense for the period.

Lease payments for operating leases, where substantially all the risks and benefits remain with the lessor, are charged as expenses on a straight-line basis over the lease term.

Revenue

Membership revenue is measured at the fair value of the consideration received and is brought to account on receipts basis.

Interest revenue is recognised proportionally using the effective interest rate method, which for floating rate financial assets is the rate inherent in the instrument.

Grant revenue is recognised in the statement of comprehensive income when the entity obtains control of the grant and it is probable that the economic benefits gained from the grant will flow to the entity and the amount of the grant can be measured reliably.

If conditions are attached to the grant which must be satisfied before it is eligible to receive the contribution, the recognition of the grant as revenue will be deferred until those conditions are satisfied.

When grant revenue is received whereby the entity incurs an obligation to deliver economic value directly back to the contributor, this is considered to be a reciprocal transaction and the grant revenue is recognised in the statement of financial position as a liability until the service has been delivered to the contributor, otherwise the grant is recognised as revenue on receipt.

Revenue from the rendering of a service is recognised upon delivery of the service to the customer.

All revenue is stated net of the amount of Goods and Service Tax ("GST").

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2020

1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

Goods and Services Tax

Revenues, expenses and assets are recognised net of the amount of GST except where the amount of GST incurred is not recoverable from the ATO, it is recognised as part of the cost of acquisition of an asset or as part of an item of expense or for receivables or payables which are recognised inclusive of GST where applicable.

The net amount of GST recoverable from, or payable to, the ATO is included as part of receivables or payables.

Trade and other payables

Trade and other payables represent the liability outstanding at the end of the reporting period for goods and services received by the company during the reporting period which remain unpaid. The balance is recognised as a current liability with the amounts normally paid within 30 days of recognition of the liability.

Employee Entitlements

Provision is made for the liability for employee entitlements arising from services rendered by employees to balance date. Employee entitlements expected to be settled within one year together with entitlements arising from wages and salaries and annual leave which will be settled after one year have been measured at their nominal amount. Other employee entitlements payable later than one year have been measured at the present value of the estimated future cash outflows to be made for those entitlements. Contributions are made to an employee superannuation fund and are charged as expenses when incurred. The company has no legal obligation to provide benefits to employees on retirement.

Cash and Cash equivalents

For the purpose of the statement of cash flows, cash includes cash on hand and at call deposits with banks or financial institutions, net of bank overdrafts

Critical Accounting Estimates and Judgments

The directors evaluate estimates and judgments incorporated into the financial report based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both externally and within the company.

Key estimates - impairment

The company assesses impairment at each reporting date by evaluating conditions specific to the company that may lead to impairment of assets. Where an impairment trigger exists, the recoverable amount of the asset is determined. Value-in-use or current replacement calculations performed in assessing recoverable amounts incorporate a number of key estimates.

Comparative figures

When required by accounting standards, comparative figures have been adjusted to conform to changes in presentation for the current year. The comparative for the 2018 year represent the period 14 September 2018 to 31 December 2018. Prior to this ASID was an incorporated association.

Liability of Members'

The company is limited by guarantee. If the company is wound up, Clause 9 of the Constitution states that in the event of there being a deficiency of net assets on winding up, each member and members within one year of ceasing to be members undertake to contribute a sum not exceeding one dollar per person. As at 31 December 2020 the number of members was 1,069

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2020

1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

New Accounting Standards for Application in Future Periods

The AASB has issued a number of new and amended Accounting Standards that have mandatory application dates for future reporting periods, some of which are relevant to the Association. The directors have decided not to early adopt any of the new and amended pronouncements. The Association's assessment of the new and amended pronouncements that are relevant to the Association but applicable in future reporting periods is set out below:

- AASB 9: *Financial Instruments* and associated Amending Standards (applicable to annual reporting periods beginning on or after 1 January 2018).

The Standard will be applicable retrospectively (subject to the provisions on hedge accounting outlined below) and includes revised requirements for the classification and measurement of financial instruments, revised recognition and derecognition requirements for financial instruments and simplified requirements for hedge accounting.

The key changes that may affect the Association on initial application include certain simplifications to the classification of financial assets, simplifications to the accounting of embedded derivatives, upfront accounting for expected credit loss, and the irrevocable election to recognize gains and losses on investments in equity instruments that are not held for trading in other comprehensive income. AASB 9 also introduces a new model for hedge accounting that will allow greater flexibility in the ability to hedge risk, particularly with respect to hedge accounting that will allow greater flexibility in the ability to hedge non-financial items. Should the Association elect to change its hedge policies in line with the new hedge accounting requirements of the standard, the application of such accounting would be largely prospective.

Although the directors anticipate that the adoption of AASB 9 may have an impact on the Association's financial instruments, including hedging activity, it is impracticable at this stage to provide a reasonable estimate of such impact.

- AASB 16: *Leases* (applicable to annual reporting periods beginning on or after 1 January 2019).

When effective, this Standard will replace the current accounting requirements applicable to leases in AASB 117: *Leases and related Interpretations*. AASB 16 introduces a single lessee accounting model that eliminates the requirement for leases to be classified as operating or finance leases.

The main changes introduced by the new Standard are as follows:

- recognition of a right-of-use and liability for all leases (excluding short-term leases with less than 12 months of tenure and leases relating to low-value assets);
- depreciation of right-of-use assets in line with AASB 116: *Property, Plant and Equipment* in profit or loss and unwinding of the liability in principal and interest components;
- inclusion of variable lease payments that depend on an index or a rate in the initial measurement of the lease liability using the index or rate at the commencement date;
- application of a practical expedient to permit a lessee to elect not to separate non-lease component and instead account for all components as a lease; and
- inclusion of additional disclosure requirements.

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2020

1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

New Accounting Standards for Application in Future Periods (continued)

The transitional provisions of AASB 16 allow a lessee to either retrospectively apply the Standard to comparatives in line with AASB 108: *Accounting Policies, Changes in Accounting Estimates and Errors* or recognise the cumulative effect of retrospective application as an adjustment to opening equity on the date of initial application.

Although the directors anticipate that the adoption of AASB 16 will impact Association's financial statements, the Association currently has a lease of less than four months and is accordingly exempt from the changes resulting from the adoption of AASB 16.

- AASB 1058: *Income of Not-For-Profit Entities* (applicable to annual reporting periods beginning on or after 1 January 2020).

This Standard is applicable to transactions that do not arise from enforceable contracts with customers involving performance obligations.

The significant accounting requirements of AASB 1058 are as follows:

- Income arising from an excess of the initial carrying amount of an asset over the related contributions by owners, increase in liabilities, decreases in assets and revenue should be immediately recognised in profit or loss. For this purpose, the assets, liabilities and revenue are to be measured in accordance with other Standards.
- Liabilities should be recognised for the excess of the initial carrying amount of a financial asset (received in a transfer to enable the entity to acquire or construct a recognisable non-financial asset that is to be controlled by the entity) over any related amounts recognised in accordance with the applicable Standards. The liabilities must be amortised to profit or loss as income when the entity satisfies its obligations under the transfer.

An entity may elect to recognise volunteer services or a class of volunteer services as an accounting policy choice if the fair value of those services can be measured reliably whether or not the services would have been purchased if they had not been donated. Recognised volunteer services should be measured at fair value and any excess over the related amounts (such as contributions by owner or revenue) immediately recognised as income in profit or loss.

The transitional provision of this Standard permit an entity to either: restate the contracts that existed in each prior period presented in accordance with AASB 108 (subject to certain practical expedients); or recognise the cumulative effect of retrospective application to incomplete contracts on the date of initial application. For this purpose, a completed contract is a contract or transaction for which the entity has recognised all of the income in accordance with AASB 1004: *Contributions*. Although the directors anticipate that the adoption of AASB 1058 may have an impact on the Association's financial statements, it is impracticable at this stage to provide a reasonable estimate of such impact.

- AASB 2016-4: *Amendments to Australian Accounting Standards – recoverable Amount of Non-Cash-Generating Specialised Assets of Not-for-Profit Entities* (applicable to annual reporting periods beginning on or after 1 January 2018).

This Standard amends AASB 136: *Impairment of Assets* to remove references to depreciated replacement cost as a measure of value in use for not-for-profit entities; and clarify that AASB 136 does not apply to non-cash-generating specialised assets that are regularly revalued to fair value under the revaluation model in AASB 116 and AASB 138: *Intangible Assets*, but applies to such assets accounted for under the cost model in those standards.

AASB 2016-4 is not expected to have a significant impact on the Society's financial statements.

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2020

	2020	2019
	\$	\$
2. Revenue		
Operating Activities		
Membership Subscriptions	222,071	251,934
Conference Income	108,088	544,848
ANZMIG Income	41,748	214,100
Special interest group income	2,037	138,523
Sponsorship	69,427	56,940
Sale of publications	64	106
Government stimulus	47,904	-
Sundry Income	-	7,057
Interest Received	14,742	14,239
	<u>506,081</u>	<u>1,227,747</u>

3. Profit (Loss) from Ordinary Activities

Profit (Loss) from ordinary activities before income tax has been determined after:

(a) Expenses:

Auditor's remuneration:

- Audit	4,716	4,938
Depreciation of plant and equipment	897	897
Employee leave provisions	<u>7,129</u>	<u>10,768</u>

4. Cash and cash equivalents

Cash at Bank – Cheque Account	483,024	643,032
Cash at Bank – Term Deposits	<u>1,593,621</u>	<u>1,382,505</u>
	<u>2,076,645</u>	<u>2,025,537</u>

The effective interest rate on short term deposits was 1.88% and these deposits have an average maturity of ninety two days.

5. Other Current Assets

Current

Prepaid Expenses	86,064	74,104
Other Debtors	<u>724</u>	<u>2,272</u>
	<u>86,788</u>	<u>76,376</u>

6. Property, plant and equipment

Plant and equipment - at cost	29,325	29,325
Less: accumulated depreciation	<u>(27,508)</u>	<u>(26,611)</u>
	<u>1,817</u>	<u>2,714</u>

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2020

	2020	2019
	\$	\$
6. Property, plant and equipment (Cont)		
Movement in carrying amounts		
Movement in carrying amounts for each class or plant and equipment between the beginning and end of the current financial year		
Balance at the beginning of the year	2,714	3,611
Depreciation expense	<u>(897)</u>	<u>(897)</u>
Carrying amount at end of year	<u>1,817</u>	<u>2,714</u>
7. Trade and other payables		
Current		
Trade Creditors & Accruals	17,319	16,822
Deferred income	<u>39,545</u>	<u>43,664</u>
	<u>56,864</u>	<u>60,486</u>
8. Provisions		
Current		
Annual Leave Entitlements	<u>24,205</u>	<u>17,076</u>
Number of employees at year end	<u>4</u>	<u>3</u>

9. Related party transactions

No Director member receives directly or indirectly any fees, bonuses or other remuneration as a consequence of their appointment to the Board.

10. Financial instruments

Financial risk management

The Company's financial instruments consist mainly of deposits with banks, local money market instruments and short-term investments, accounts receivable and payable.

The Company does not have any derivative financial instruments at 31 December 2020.

Financial Risk Management Policies

The Director's overall risk management strategy seeks to assist the Company in meeting its financial targets, whilst minimising potential adverse effects on financial performance. Risk management policies are approved and reviewed by the Directors' on a regular basis.

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2020

2020
\$

10. Financial instruments (Cont)

The totals for each category of financial instruments, measured in accordance with AASB 9 is detailed in the accounting policies to these financial statements, are as follows:

Financial assets

Cash & cash equivalents	2,076,645	2,025,537
Trade & other receivables	724	2,272
	<u>2,077,369</u>	<u>2,027,809</u>

Financial liabilities

Trade & other payables	56,864	60,486
Less Deferred revenue	(39,545)	(43,664)
Less GST payable	(11,000)	(7,955)
Financial liabilities	<u>6,319</u>	<u>8,867</u>

i. Treasury risk management

A finance committee consisting of senior Board members meet on a regular basis to analyse currency and interest rate exposure and to evaluate treasury management strategies in the context of the most recent economic conditions and forecasts.

ii. Financial risks

The main risks the Company is exposed to through its financial instruments are interest rate risk, liquidity risk and credit risk.

Interest rate risk

All financial assets and liabilities are non-interest bearing except for the following:
Cash assets at an average interest rate for the year of 0.71%

Foreign currency risk

The Company is not exposed to fluctuations in foreign currencies

Interest rate risk

The Company's exposure to interest rate risk, which is the risk that a financial instrument's value will fluctuate as a result of changes in market interest rates and will affect future cash flows or the fair value of fixed rate financial instruments.

Floating rate instruments

Cash & cash equivalents	<u>2,076,645</u>	<u>2,025,537</u>
-------------------------	------------------	------------------

Liquidity risk

Liquidity risk arises from the possibility that the Company might encounter difficulty in settling its debts or otherwise meeting its obligations related to financial liabilities

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2020

	2020	2019
	\$	\$
10. Financial instruments (continued)		

The Company manages this risk through the following mechanisms:

- preparing forward-looking cash flow analysis in relation to its operational, investing and financing activities;
- obtaining funding from various sources
- maintaining a reputable credit profile
- managing credit risk related to financial assets
- only investing surplus cash with major financial institutions
- comparing the maturity profile of financial liabilities with the realisation profile of financial assets.

Financial liability and financial asset maturity analysis

	Within one year	
<i>Financial liabilities due for payment:</i>		
Trade & other payables excluding deferred income and GST payable	6,319	8,867
Total expected outflows	6,319	8,867
<i>Financial assets – cash flows realisable:</i>		
Cash & cash equivalents	2,076,645	2,025,537
Trade & other receivables	724	2,272
Total anticipated inflows	2,077,369	2,027,809
Net (outflows) inflows on financial instruments	2,071,050	2,018,942

Foreign exchange risk

The Company is exposed to fluctuations in foreign currencies due to the New Zealand denominated account held during the period.

Credit risk

Exposure to credit risk relating to financial assets arises from the potential non-performance by counterparties of contractual obligations that could lead to a financial loss to the Company. Credit risk is managed through maintaining procedures ensuring, to the extent possible, that customers and counterparties to transactions are of sound credit worthiness and includes utilisation of systems for that approval, granting and renewal of credit limits, the regular monitoring of exposures against such limits and the monitoring of the financial stability of significant customers and counterparties. Such monitoring is used in assessing receivables for impairment. Credit terms are normally 14-30 days from the date of invoice.

Customers that do not meet the Company's strict credit policies may only purchase in cash or using recognised credit cards.

Risk is also minimised through investing surplus funds in financial institutions that maintain high credit ratings or in entities that the finance committee has otherwise cleared as being financially sound.

The maximum exposure to credit risk by class of recognised financial assets at balance date, excluding the value of any collateral or other security held, is equivalent to the carrying value and classification of those financial assets (net of any provisions) as presented in the balance sheet.

The company has no significant concentration of credit risk with any single counterparty or group of counterparties.

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2020

	2020	2019
	\$	\$
10. Financial instruments (continued)		

Trade & other receivables that are neither past due or impaired are considered to be of high credit quality aggregates of such amounts are as detailed in Note 5

The Company does not have any material credit risk exposure to any single receivable or group of receivables under financial instruments entered in to by the Company.

Credit risk related to balances with banks and other financial institutions is managed by the finance committee in accordance with approved Committee policy. The following table provides information regarding the credit risk relating to cash based on S&P counterparty credit ratings.

Cash and cash equivalents

- A+ rated	708,323	700,000
- AA- rated	<u>1,368,322</u>	<u>1,325,537</u>

Price risk

The company is not exposed to any material commodity price risk.

Net fair values

Fair value estimation

The fair values of financial assets and financial liabilities are presented in the following table and can be compared to their carrying values as presented in the balance sheet. Fair values are those amounts at which an asset could be exchanged, or a liability settled, between knowledgeable, willing parties in an arms-length transaction. Fair values derived may be based on information that is estimated or subject to judgement, where changes in assumptions may have a material impact on the amounts estimated, Areas of judgement and the assumptions have been detailed below.

Differences between fair values and carrying values of financial instruments with fixed interest rates are due to the change in discount rates being applied by the market since their initial recognition by the company.

	2020		2019	
	Net carrying value	Net fair value	Net carrying value	Net fair value
Financial assets				
Cash & cash equivalents	2,076,645	2,076,645	2,025,537	2,025,537
Trade & other receivables	<u>724</u>	<u>724</u>	<u>2,272</u>	<u>2,272</u>
Total financial assets	<u>2,077,369</u>	<u>2,077,369</u>	<u>2,027,809</u>	<u>2,027,809</u>
Financial Liabilities				
Trade & other payables	<u>6,319</u>	<u>6,319</u>	<u>8,867</u>	<u>8,867</u>
Total financial liabilities	<u>6,319</u>	<u>6,319</u>	<u>8,867</u>	<u>8,867</u>

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

	2020	2019
	\$	\$
10. Financial instruments (continued)		
The fair values of these financial assets have been based on the closing quoted bid prices at the end of the reporting period, excluding transaction costs.		
The fair values disclosed in the above table have been determined based on the following methodologies:		
(i)	Cash and cash equivalents, trade and other receivables and trade and other payables are short term instruments in nature whose carrying value is equivalent to fair value.	

Sensitivity analysis

The following table illustrates sensitivities to the company's exposures to changes in interest rates and equity prices. The table indicates the impact on how profit and equity values reporting at the end of the reporting period would have been affected by changes in the relevant risk variable that management considers to be reasonably possible. These sensitivities assume that the movement in a particular variable is independent of other variables.

	Profit	Equity
	\$	\$
Year ended 31 December 2020		
+/- 2% in interest rates	40,843	37,699

No sensitivity analysis has been performed on foreign exchange risk as it is not considered to be material to the company.

11. Cash Flow Information

- (a) Reconciliation of net cash provided by operating activities to profit (loss) from ordinary activities after income tax

Operating Profit (Loss) after Income Tax	57,116	263,076
Non-Cash Flows in Operating Profit:		
- Depreciation	897	897
Changes in Assets and Liabilities:		
- (Increase) Decrease in Other Assets	(10,412)	(24,300)
- Increase (Decrease) in Payables	(3,622)	23,315
- Increase (Decrease) in Provisions	7,129	10,768
Net Cash (used in) provided by Operating Activities	51,108	273,756

- (b) The company has no credit stand-by or financing facilities in place.
(c) There were no non-cash financing or investing activities during the year.

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

A.B.N. 20 108 151 093

NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 DECEMBER 2020

12. Contingent Liabilities and Contingent Assets

The company is not aware of any contingent liabilities that are in existence at the date of the signing of this report.

13. Events after the Balance Sheet Date

The Covid 19 pandemic has been significantly affecting the financial environment. There is a possibility that it will significantly affect the operations of the Society, the results of these operations or the state of affairs of the Society in future financial years.

As at the date of this report, it is not possible to reliably estimate the financial effect (if any) of the virus on the Society's operations.

Apart from the effect of Covid 19, there has not arisen in the interval between the end of the financial year and the date of this report any item, transaction or event of a material or unusual nature, which in the opinion of the Director's will affect significantly the operations of the company, the results of these operations or the state of affairs of company in future financial years.

14. Company Details

The principal place of business of the company is:
Australasian Society for Infectious Diseases Ltd
Level 3 478 George Street
SYDNEY NSW 2000

The company's registered office is:
Australasian Society for Infectious Diseases Ltd
Level 3 478 George Street
SYDNEY NSW 2000

TINWORTH & Co

CHARTERED ACCOUNTANTS and BUSINESS ADVISORS

COMPILATION REPORT

TO AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD

On the basis of information provided by the directors of the Australasian Society for Infectious Diseases Ltd, we have compiled in accordance with APES 315: 'Statement on Compilation of Financial Reports', the special purpose financial report of the Australasian Society for Infectious Diseases Ltd for the period ended 31st December 2020, as set out in the attached Detailed Profit and Loss Statement.


The specific purpose for which the special purpose financial report has been prepared is to provide private information to the directors. The extent to which Accounting Standards and other mandatory professional reporting requirements have or have not been adopted in the preparation of the special purpose financial report set out in Note 1.

The directors are solely responsible for the information contained in the special purpose financial report and have determined that the accounting policies used are and are appropriate to satisfy the requirements of the directors.

Our procedures use accounting expertise to collect, classify and summarise the financial information, which the directors provided, into a financial report. Our procedures do not include verification or validation procedures. No audit or review has been performed and accordingly no assurance is expressed.

To the extent permitted by law, we do not accept liability for any loss or damage which any person, other than the company, may suffer arising from any negligence on our part. No person should rely on the special purpose financial report without having an audit or review conducted.

The special purpose financial report was prepared for the benefit of the company and its members and the purpose identified above. We do not accept responsibility to any other person for the contents of the special purpose financial report.



MARK TINWORTH
CHARTERED ACCOUNTANT

North Sydney, *1/ March* 2021

WWW.TINWORTH.COM

LEVEL 2, 66 BERRY ST NORTH SYDNEY NSW 2060 | P (02) 9922 4644 | F (02) 9959 3642 | ABN 43 624 513 140

Liability limited by a scheme approved under Professional Standards Legislation

AUSTRALASIAN SOCIETY FOR INFECTIOUS DISEASES LTD
A.B.N. 20 108 151 093

PRIVATE INFORMATION FOR THE DIRECTORS
ON THE 2020 FINANCIAL STATEMENTS

CONSOLIDATED PROFIT AND LOSS STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2020

	2020	2019
	\$	\$
INCOME		
Membership income	222,071	251,934
Conference income	108,088	544,848
Sponsorship	69,427	56,940
ANZMIG funds	41,748	214,100
Government stimulus	47,904	-
Forbes week	-	23,789
Perinatal infections Course	-	95,660
VHSIG income	-	2,823
Trainee weekend	-	3,413
Interest received	14,742	14,239
Sundry income	2,101	7,163
WSPID income	-	12,838
	<u>506,081</u>	<u>1,227,747</u>
EXPENDITURE		
Audit fees	4,716	4,938
Accountancy fees	4,160	1,400
Bank fees	5,863	12,593
Board expenses	3,038	9,946
Computer website expenses	9,775	6,298
Conference expenses	87,713	558,251
ANZMIG expenses	22,597	27,151
ANZPID expenses	4,456	9,778
HICSIG expenses	519	4,387
Depreciation	897	897
Foreign exchange	-	3,929
Forbes week expenses	-	17,259
Perinatal Infections course	-	41,940
General expenses	-	3,993
ZooSig expenses	-	2,182
Insurance	7,363	8,628
Legal expenses	200	480
Rent	19,862	22,676
Meeting expenses - NZ	-	393
Meeting expenses – Adv Trainee	-	5,917
Meeting expenses	6,106	-
Awards & grants	34,000	32,097
Secretariat expenses	12,931	3,403
Secretariat payroll expenses	<u>224,769</u>	<u>186,135</u>
	<u>448,965</u>	<u>964,671</u>
Profit before Income Tax	<u>57,116</u>	<u>263,076</u>

This financial statement should be read in conjunction with the attached Compilation Report